Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Molecular Prognostic Biomarker Found for CNS Lymphoma

By LabMedica International staff writers
Posted on 24 Jan 2019
Primary central nervous system lymphoma (PCNSL), a rare subgroup of diffuse large B-cell lymphoma (DLBCL) arising in the central nervous system (CNS), is an aggressive malignant variant of nodal non-Hodgkin lymphoma (NHL). More...
PCNSLs account for 3% of all primary CNS tumors and 1% of NHLs in adults.

MicroRNAs (miRNAs) are small noncoding regulatory RNAs consisting of approximately 20-mer nucleotides, that inhibit gene function through suppression of translation of target genes. Dysregulation of miRNA expression and RNA interference (RNAi) mechanism are related to tumor malignancy in chronic lymphocytic leukemia and acute lymphoblastic leukemia.

Scientists at Kyoto Prefectural University of Medicine (Kyoto, Japan) and their colleagues deciphered the miRNA signature through analysis between the expression patterns of miRNAs and their correlation to the prognosis in 27 PCNSL specimens. They first selected 16 miRNA candidates from the 847 miRNAs detected using microarray technique. Then based on principal component analysis (PCA) after Random forest analysis and clustering analysis, they determined that miR-181b, miR-30d, and miR-93 constituted a miRNA signature in PCNSL.

Total RNA was extracted from approximately 100 mg of each tumor tissue and the quality of the extracted RNA was verified with a Bioanalyzer System using RNA Pico Chips. The RNA was amplified twice and used for hybridization with Affymetrix GeneChip miRNA Array, comprising of 30,424 probes. After hybridization, the array chips for target detection were processed, washed, and stained using the Fluidics Station 450. The High-Resolution Microarray Scanner 3000 was used for scanning the signal, and GCOS Workstation Version 1.3 was employed for image-quality analysis.

The team considered the prognostic clues provided by the 16-miRNA gene set, and by a subset of three quantitative PCR-validated miRNAs found by Random forest analysis and clustering analyses: miR-30d, miR-93, and miR-181b. The expression profiles for miRNAs from both signatures could successfully separate PCNSL patients with poor or more favorable overall survival rates. These miRNAs have been implicated in processes ranging from new blood vessel formation to cell migration, proliferation, and immune function, the team noted, and were highly expressed in almost half the PCNSLs tested. The study was published on January 7, 2019, in the journal Public Library of Science ONE.

Related Links:
Kyoto Prefectural University of Medicine


New
Gold Member
Hematology Analyzer
Medonic M32B
Collection and Transport System
PurSafe Plus®
New
Rapid Molecular Testing Device
FlashDetect Flash10
New
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.